Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

PURPOSE: Denosumab, an anti–RANK ligand monoclonal antibody, significantly increases bone metastasis–free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant prostate cancer (CRPC) and baseline prostate-specific a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Smith, Matthew R., Saad, Fred, Oudard, Stephane, Shore, Neal, Fizazi, Karim, Sieber, Paul, Tombal, Bertrand, Damiao, Ronaldo, Marx, Gavin, Miller, Kurt, Van Veldhuizen, Peter, Morote, Juan, Ye, Zhishen, Dansey, Roger, Goessl, Carsten
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3795889/
https://ncbi.nlm.nih.gov/pubmed/24043751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.6716
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares